Abstract:Mutations in GBA1, the gene encoding the lysosomal enzyme glucocerebrosidase, are among the most common known genetic risk factors for the development of Parkinson disease and related synucleinopathies. A great deal is known about GBA1, as mutations in GBA1 are causal for the rare autosomal storage disorder Gaucher disease. Over the past decades, significant progress has been made in understanding the genetics and cell biology of glucocerebrosidase. A least 495 different mutations, found throughout the 11 exons of the gene are reported, including both common and rare variants. Mutations in GBA1 may lead to degradation of the protein, disruptions in lysosomal targeting and diminished performance of the enzyme in the lysosome.Gaucher disease is phenotypically diverse and has both neuronopathic and non-neuronopathic forms. Both patients with Gaucher disease and heterozygous carriers are at increased risk of developing Parkinson disease and Dementia with Lewy Bodies, although our understanding of the mechanism for this association remains incomplete. There appears to be an inverse relationship between glucocerebrosidase and α-synuclein levels, and even patients with sporadic Parkinson disease have decreased glucocerebrosidase. Glucocerebrosidase may interact with α-synuclein to maintain basic cellular functions, or impaired glucocerebrosidase could contribute to Parkinson pathogenesis by disrupting lysosomal homeostasis, enhancing endoplasmic reticulum stress or contributing to mitochondrial impairment. However, the majority of patients with GBA1 mutations never develop parkinsonism, so clearly other risk factors play a role. Treatments for Gaucher disease have been developed that increase visceral glucocerebrosidase levels and decrease lipid storage, although they have yet to properly address the neurological defects associated with impaired glucocerebrosidase. Mouse and induced pluripotent stem cell derived models have improved our understanding of glucocerebrosidase function and the consequences of its deficiency. These models have been used to test novel therapies including chaperone proteins, histone deacetylase inhibitors, and gene therapy approaches that enhance glucocerebrosidase levels and could prove efficacious in the treatment of forms of parkinsonism. Consequently, this rare monogenic disorder, Gaucher disease, provides unique insights directly applicable to our understanding and treatment of Parkinson disease, a common and complex neurodegenerative disorder.

Mutations of glucocerebrosidase gene and susceptibility to Parkinson’s disease: An updated meta-analysis in a European population

Mutations in GBA and risk of Parkinson's disease: a meta-analysis based on 25 case-control studies.

Four novel rare mutations of PLA2G6 in Chinese population with Parkinson's disease.

Glucocerebrosidase gene L444P mutation is a risk factor for Parkinson's disease in Chinese population.

Glucocerebrosidase L444P Mutation Confers Genetic Risk for Parkinson’s Disease in Central China

Effects of glucocerebrosidase gene polymorphisms and mutations on the risk of Parkinson's disease dementia: A meta-analysis

A Novel P.l216i Mutation in the Glucocerebrosidase Gene is Associated with Parkinson's Disease in Han Chinese Patients.

Association Of The Glucocerebrosidase N370s Allele With Parkinson'S Disease In Two Separate Chinese Han Populations Of Mainland China

Increased Incidence of Parkinsonism among Chinese with Β-Glucosidase Mutation in Central Taiwan

Glucocerebrosidase Mutations Cause Mitochondrial and Lysosomal Dysfunction in Parkinson's Disease: Pathogenesis and Therapeutic Implications

Glucocerebrosidase Mutations Cause Mitochondrial and Lysosomal Dysfunction in Parkinson’s Disease: Pathogenesis and Therapeutic Implications

Mutational Spectrum and Clinical Features of GBA1 Variants in a Chinese Cohort with Parkinson’s Disease

Association Analysis and Polygenic Risk Score Evaluation of 38 Gwas-Identified Loci in A Chinese Population with Parkinson'S Disease

Characterization of a pathogenic variant in GBA for Parkinson’s disease with mild cognitive impairment patients

Association Between GBA L444P Mutation and Sporadic Parkinson's Disease from Mainland China

Glucocerebrosidase Mutations Influence the Natural History of Parkinson's Disease in a Community-Based Incident Cohort.

Genetic Association Study of Glucocerebrosidase Gene L444P Mutation in Essential Tremor and Multiple System Atrophy in Mainland China

Association between bone marrow stromal cell antigen 1 gene polymorphisms and the susceptibility to Parkinson's disease: a meta-analysis.

Clinical, mechanistic, biomarker, and therapeutic advances in GBA1-associated Parkinson's disease

Glucocerebrosidase and its relevance to Parkinson disease

A Global Perspective of GBA1-Related Parkinson's Disease: A Narrative Review